The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
There's no shortage of cancer immunotherapies trying ... Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months ...
In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers ... for it (other than from Seeking Alpha). I have no business relationship with any company whose ...
With these results, Libtayo now has the potential to also transform the treatment of high-risk resectable CSCC with adjuvant treatment.” Lead C-POST investigator, Danny Rischin, the Peter MacCallum ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback